A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A phase 2 trial of Nirogacestat in desmoid tumour, run by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, active and no longer recruiting.
Overview
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) is a phase 2 interventional study registered as NCT07170644 by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, with 20 participants enrolled, started 2025-08-08 and due to reach its primary completion in 2027-05-28. Interventions recorded: Nirogacestat oral tablet. Conditions listed: Desmoid Tumor, Aggressive Fibromatosis. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TargetGamma-secretase (PSEN1)
Shares Nirogacestat, Desmoid tumour.
- TrialDeFi
Shares Nirogacestat, Desmoid tumour.
- CompanySpringWorks Therapeutics (Merck KGaA)
Shares Nirogacestat, Desmoid tumour.
- IdeaIntermittent or stop-and-restart nirogacestat in desmoid tumours
Shares Nirogacestat, Desmoid tumour.
- PathwayNotch signalling
Shares Nirogacestat, Desmoid tumour.
- CompanyMerck KGaA (EMD Serono)
Shares Nirogacestat, Desmoid tumour.
- PathwayWnt / β-catenin
Shares Nirogacestat, Desmoid tumour.